Logo

Innovent and AnHeart Therapeutics Report the NMPA’s Acceptance of Second NDA for Taletrectinib to Treat Lung Cancer

Share this
Innovent

Innovent and AnHeart Therapeutics Report the NMPA’s Acceptance of Second NDA for Taletrectinib to Treat Lung Cancer

Shots:

  • The NMPA has accepted second NDA of taletrectinib adipate capsule for the 1L treatment of locally advanced or metastatic ROS1+ NSCLC adult patients previously untreated with ROS1 TKIs
  • Both the NDAs were supported by the data from P-II (TRUST-I) study highlighted at the European Lung Cancer Congress (ELCC) 2023 and additional data from TRUST-I is planned to be presented at an upcoming medical meeting in 2024. The first NDA for the drug was accepted in Nov 2023 and was granted priority review for the same indication
  • Taletrectinib is an orally administered, brain-penetrating, selective, next-generation ROS1 inhibitor indicated for the treatment of NSCLC

Ref: Innovent | Image: Innovent

Related News:- The NMPA Accepts Anheart Therapeutics & Innovent’s NDA for Taletrectinib and Grants Priority Review for the Treatment of Non-Small Cell Lung Cancer

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Disha Nankani

Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions